{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T09:08:26Z","timestamp":1768554506979,"version":"3.49.0"},"posted":{"date-parts":[[2022,3,7]]},"group-title":"Infectious Diseases (except HIV\/AIDS)","reference-count":46,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2022,3,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  This network meta-analysis (NMA) assessed the efficacy of remdesivir in hospitalized patients with COVID-19 requiring supplemental oxygen. Randomized controlled trials of hospitalized patients with COVID-19, where patients were receiving supplemental oxygen at baseline and at least one arm received treatment with remdesivir, were identified. Outcomes included mortality, recovery, and no longer requiring supplemental oxygen. NMAs were performed for low-flow oxygen (LFO\n                  <jats:sub>2<\/jats:sub>\n                  ); high-flow oxygen (HFO\n                  <jats:sub>2<\/jats:sub>\n                  ), including NIV; or oxygen at any flow (AnyO\n                  <jats:sub>2<\/jats:sub>\n                  ) at early (day 14\/15) and late (day 28\/29) time points. Six studies were included (N=5,245 patients) in the NMA. Remdesivir lowered early and late mortality among AnyO\n                  <jats:sub>2<\/jats:sub>\n                  patients (risk ratio (RR) 0.52, 95% credible interval (CrI) 0.34-0.79; RR 0.81, 95%CrI 0.69-0.95) and LFO\n                  <jats:sub>2<\/jats:sub>\n                  patients (RR 0.21, 95%CI 0.09-0.46; RR 0.24, 95%CI 0.11-0.48); no improvement was observed among HFO\n                  <jats:sub>2<\/jats:sub>\n                  patients. Improved early and late recovery was observed among LFO\n                  <jats:sub>2<\/jats:sub>\n                  patients (RR 1.22, 95%CrI 1.09-1.38; RR 1.17, 95%CrI 1.09-1.28). Remdesivir also lowered the requirement for oxygen support among all patient subgroups. Among hospitalized patients with COVID-19 requiring supplemental oxygen at baseline, use of remdesivir compared to best supportive care is likely to improve the risk of mortality, recovery and need for oxygen support in AnyO\n                  <jats:sub>2<\/jats:sub>\n                  and LFO\n                  <jats:sub>2<\/jats:sub>\n                  patients.\n                <\/jats:p>","DOI":"10.1101\/2022.03.04.22271706","type":"posted-content","created":{"date-parts":[[2022,3,8]],"date-time":"2022-03-08T01:20:10Z","timestamp":1646702410000},"source":"Crossref","is-referenced-by-count":1,"title":["Remdesivir for the treatment of patients hospitalized with COVID-19 receiving supplemental oxygen: a targeted literature review and meta-analysis"],"prefix":"10.64898","author":[{"given":"Rachel","family":"Beckerman","sequence":"first","affiliation":[]},{"given":"Andrea","family":"Gori","sequence":"additional","affiliation":[]},{"given":"Sushanth","family":"Jeyakumar","sequence":"additional","affiliation":[]},{"given":"Jakob J.","family":"Malin","sequence":"additional","affiliation":[]},{"given":"Roger","family":"Paredes","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"P\u00f3voa","sequence":"additional","affiliation":[]},{"given":"Nate","family":"Smith","sequence":"additional","affiliation":[]},{"given":"Armando","family":"Teixeira-Pinto","sequence":"additional","affiliation":[]}],"member":"54368","reference":[{"issue":"4","key":"2022030912201174000_2022.03.04.22271706v1.1","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3390\/jcm9041225","article-title":"The COVID-19 Pandemic: A Comprehensive Review of Taxonomy, Genetics, Epidemiology, Diagnosis, Treatment, and Control","volume":"9","year":"2020","journal-title":"Journal of clinical medicine"},{"issue":"3","key":"2022030912201174000_2022.03.04.22271706v1.2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S2213-2600(20)30527-0","article-title":"Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study","volume":"9","year":"2021","journal-title":"The Lancet Respiratory Medicine"},{"key":"2022030912201174000_2022.03.04.22271706v1.3","doi-asserted-by":"crossref","unstructured":"Al-Aly Z , Xie Y , Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature. 2021.","DOI":"10.1038\/s41586-021-03553-9"},{"issue":"1","key":"2022030912201174000_2022.03.04.22271706v1.4","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1186\/s13054-021-03588-4","article-title":"Relationship between ventilator-associated pneumonia and mortality in COVID-19 patients: a planned ancillary analysis of the coVAPid cohort","volume":"25","year":"2021","journal-title":"Critical Care"},{"key":"2022030912201174000_2022.03.04.22271706v1.5","doi-asserted-by":"crossref","unstructured":"Grasselli G , Scaravilli V , Mangioni D , et al. Hospital-Acquired Infections in Critically Ill Patients With COVID-19. Chest. 2021.","DOI":"10.1186\/s13054-021-03672-9"},{"key":"2022030912201174000_2022.03.04.22271706v1.6","doi-asserted-by":"crossref","unstructured":"Malin JJ , Su\u00e1rez I , Priesner V , F\u00e4tkenheuer G , Rybniker J. Remdesivir against COVID-19 and Other Viral Diseases. Clin Microbiol Rev. 2020;34(1).","DOI":"10.1128\/CMR.00162-20"},{"issue":"1","key":"2022030912201174000_2022.03.04.22271706v1.7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41467-020-20542-0","article-title":"Mechanism of SARS-CoV-2 polymerase stalling by remdesivir","volume":"12","year":"2021","journal-title":"Nature Communications"},{"key":"2022030912201174000_2022.03.04.22271706v1.8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"issue":"9","key":"2022030912201174000_2022.03.04.22271706v1.9","first-page":"795","article-title":"Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19","volume":"384","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"6","key":"2022030912201174000_2022.03.04.22271706v1.10","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2023184","article-title":"Repurposed Antiviral Drugs for Covid-19 \u2014 Interim WHO Solidarity Trial Results","volume":"384","author":"WHO Solidarity Trial Consortium","year":"2020","journal-title":"New England Journal of Medicine"},{"key":"2022030912201174000_2022.03.04.22271706v1.11","doi-asserted-by":"crossref","first-page":"106272","DOI":"10.1016\/j.cct.2021.106272","article-title":"Remdesivir for the treatment of COVID-19: A systematic review and meta-analysis of randomized controlled trials","volume":"101","year":"2021","journal-title":"Contemporary clinical trials"},{"key":"2022030912201174000_2022.03.04.22271706v1.12","doi-asserted-by":"crossref","unstructured":"Alexander PE , Piticaru J , Lewis K , et al. Remdesivir use in patients with coronavirus COVID-19 disease: a systematic review and meta-analysis of the Chinese Lancet trial with the NIH trial. medRxiv. 2020:2020.2005.2023.20110932.","DOI":"10.1101\/2020.05.23.20110932"},{"key":"2022030912201174000_2022.03.04.22271706v1.13","doi-asserted-by":"crossref","first-page":"173926","DOI":"10.1016\/j.ejphar.2021.173926","article-title":"Remdesivir for treatment of COVID-19; an updated systematic review and meta-analysis","volume":"897","year":"2021","journal-title":"European journal of pharmacology"},{"key":"2022030912201174000_2022.03.04.22271706v1.14","doi-asserted-by":"crossref","unstructured":"Elsawah HK , Elsokary MA , Abdallah MS , ElShafie AH . Efficacy and safety of remdesivir in hospitalized Covid-19 patients: Systematic review and meta-analysis including network meta-analysis. Rev Med Virol. 2020:e2187.","DOI":"10.1002\/rmv.2187"},{"issue":"2","key":"2022030912201174000_2022.03.04.22271706v1.15","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1002\/jmv.26443","article-title":"Effectiveness of remdesivir for the treatment of hospitalized COVID-19 persons: A network meta-analysis","volume":"93","year":"2021","journal-title":"Journal of medical virology"},{"issue":"12","key":"2022030912201174000_2022.03.04.22271706v1.16","doi-asserted-by":"crossref","first-page":"e0243705","DOI":"10.1371\/journal.pone.0243705","article-title":"Efficacy and harms of remdesivir for the treatment of COVID-19: A systematic review and meta-analysis","volume":"15","year":"2020","journal-title":"PLoS One"},{"key":"2022030912201174000_2022.03.04.22271706v1.17","doi-asserted-by":"crossref","first-page":"118663","DOI":"10.1016\/j.lfs.2020.118663","article-title":"Remdesivir: A potential game-changer or just a myth? A systematic review and meta-analysis","volume":"264","year":"2021","journal-title":"Life sciences"},{"key":"2022030912201174000_2022.03.04.22271706v1.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2020.198137"},{"key":"2022030912201174000_2022.03.04.22271706v1.19","doi-asserted-by":"crossref","unstructured":"Morris A , Juni P , Odutayo A , al. e. Remdesivir for hospitalized patients with COVID-19.. Science Briefs of the Ontario COVID-19 Science Advisory Table. 2021;2(27).","DOI":"10.47326\/ocsat.2021.02.27.1.0"},{"key":"2022030912201174000_2022.03.04.22271706v1.20","first-page":"Cd014962","article-title":"Remdesivir for the treatment of COVID-19","volume":"8","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2022030912201174000_2022.03.04.22271706v1.21","doi-asserted-by":"crossref","unstructured":"Lee TC , Murthy S , Del Corpo O , et al. Remdesivir for the Treatment of COVID-19: An Updated Systematic Review and Meta-Analysis. medRxiv. 2022:2022.2001.2022.22269545.","DOI":"10.1101\/2022.01.22.22269545"},{"key":"2022030912201174000_2022.03.04.22271706v1.22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2535"},{"issue":"Suppl 1","key":"2022030912201174000_2022.03.04.22271706v1.23","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.4103\/ija.IJA_149_21","article-title":"Clinical outcomes of using remdesivir in patients with moderate to severe COVID-19: A prospective randomised study","volume":"65","year":"2021","journal-title":"Indian journal of anaesthesia"},{"key":"2022030912201174000_2022.03.04.22271706v1.24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"issue":"19","key":"2022030912201174000_2022.03.04.22271706v1.25","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1056\/NEJMoa2015301","article-title":"Remdesivir for 5 or 10 Days in Patients with Severe Covid-19","volume":"383","year":"2020","journal-title":"New England Journal of Medicine"},{"issue":"11","key":"2022030912201174000_2022.03.04.22271706v1.26","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19: A Randomized Clinical Trial","volume":"324","year":"2020","journal-title":"JAMA"},{"key":"2022030912201174000_2022.03.04.22271706v1.27","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X13487604"},{"key":"2022030912201174000_2022.03.04.22271706v1.28","doi-asserted-by":"publisher","DOI":"10.1177\/0272989X12458724"},{"key":"2022030912201174000_2022.03.04.22271706v1.29","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-019-0829-2"},{"key":"2022030912201174000_2022.03.04.22271706v1.30","unstructured":"Dias S , Welton NJ , Sutton AJ , Caldwell DM , Lu G , Ades AE . NICE Decision Support Unit Technical Support Documents. In: NICE DSU Technical Support Document 4: Inconsistency in Networks of Evidence Based on Randomised Controlled Trials.2014."},{"key":"2022030912201174000_2022.03.04.22271706v1.31","unstructured":"Olender SA , Perez KK , Go AS , et al. Remdesivir for Severe COVID-19 versus a Cohort Receiving Standard of Care. Clin Infect Dis. 2020."},{"key":"2022030912201174000_2022.03.04.22271706v1.32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31022-9"},{"key":"2022030912201174000_2022.03.04.22271706v1.33","unstructured":"Mozaffari E , Chandak A , Zhang Z , et al. Remdesivir treatment is associated with improved survival in hospitalized patients with COVID-19. Paper presented at: World Microbe Forum2021; Virtual."},{"key":"2022030912201174000_2022.03.04.22271706v1.34","unstructured":"Go A , Malenica I , Fusco D , et al. Remdesivir versus standard of care for severe COVID-19. Paper presented at: World Microbe Forum2021; Virtual."},{"key":"2022030912201174000_2022.03.04.22271706v1.35","unstructured":"National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing COVID-19. NICE guideline [NG191]. 2021."},{"key":"2022030912201174000_2022.03.04.22271706v1.36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.18773\/austprescr.2020.060","volume":"43","author":"Remdesivir for COVID-19","year":"2020","journal-title":"Aust Prescr"},{"issue":"3","key":"2022030912201174000_2022.03.04.22271706v1.37","doi-asserted-by":"crossref","first-page":"e213071","DOI":"10.1001\/jamanetworkopen.2021.3071","article-title":"Comparison of Time to Clinical Improvement With vs Without Remdesivir Treatment in Hospitalized Patients With COVID-19","volume":"4","year":"2021","journal-title":"JAMA Network Open"},{"issue":"1","key":"2022030912201174000_2022.03.04.22271706v1.38","doi-asserted-by":"crossref","first-page":"e13","DOI":"10.1016\/S2666-5247(20)30172-5","article-title":"SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis","volume":"2","year":"2021","journal-title":"Lancet Microbe"},{"key":"2022030912201174000_2022.03.04.22271706v1.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2027040"},{"key":"2022030912201174000_2022.03.04.22271706v1.40","unstructured":"National Institutes of Health. COVID-19 Treatment Guideliens Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines.. https:\/\/www.covid19treatmentguidelines.nih.gov\/. Published 2019. Accessed June 25, 2021."},{"key":"2022030912201174000_2022.03.04.22271706v1.41","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m3379"},{"key":"2022030912201174000_2022.03.04.22271706v1.42","doi-asserted-by":"crossref","unstructured":"Gu\u00e9rin PJ , McLean ARD , Rashan S , et al. Definitions matter: heterogeneity of COVID-19 disease severity criteria and incomplete reporting compromise meta-analysis. medRxiv. 2021:2021.2006.2004.21257852.","DOI":"10.1101\/2021.06.04.21257852"},{"key":"2022030912201174000_2022.03.04.22271706v1.43","unstructured":"European Medicines Agency Human Medicines Committee. Annex I: Conditions for use of remdesivir. 2020."},{"key":"2022030912201174000_2022.03.04.22271706v1.44","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m2980"},{"key":"2022030912201174000_2022.03.04.22271706v1.45","unstructured":"Kalil AC , Mehta AK , Patterson TF , et al. Efficacy of interferon beta-1a plus remdesivir compared with remdesivir alone in hospitalised adults with COVID-19: a double-bind, randomised, placebo-controlled, phase 3 trial. Lancet Respir Med. 2021."},{"key":"2022030912201174000_2022.03.04.22271706v1.46","unstructured":"Ader F , Bouscambert-Duchamp M , Hites M , et al. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. The Lancet Infectious Diseases."}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2022.03.04.22271706","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T14:38:26Z","timestamp":1768487906000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2022.03.04.22271706"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,7]]},"references-count":46,"URL":"https:\/\/doi.org\/10.1101\/2022.03.04.22271706","relation":{"is-preprint-of":[{"id-type":"doi","id":"10.1038\/s41598-022-13680-6","asserted-by":"subject"}]},"subject":[],"published":{"date-parts":[[2022,3,7]]},"subtype":"preprint"}}